Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Risk Score Detects Glaucoma and Predicts Progression of the Disease

By LabMedica International staff writers
Posted on 28 Jan 2020
Establishment of a glaucoma polygenic risk score (PRS) will facilitate the development of a personalized approach for earlier treatment of high-risk individuals, with less intensive monitoring and treatment being possible for lower-risk groups.

Glaucoma is a group of eye diseases, which cause damage to the optic nerve that can result in vision loss. More...
The most common type is open-angle glaucoma, in which the drainage angle for fluid within the eye remains open, with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Peripheral vision may begin to decrease, followed by central vision, resulting in blindness if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent. Risk factors for glaucoma include increased pressure in the eye, a family history of the condition, and high blood pressure.

Investigators at QIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute (Brisbane, Australia) and Flinders University (Bedford Park, Australia) reported that they had identified 107 genes that increased a person's risk of developing glaucoma.

The investigators found that individuals in the top PRS decile reached an absolute risk for glaucoma 10 years earlier than the bottom decile and were at 15-fold increased risk of developing advanced glaucoma. Furthermore, the PRS predicted glaucoma progression in prospectively monitored, early manifest glaucoma cases and surgical intervention in advanced disease.

"Glaucoma is a genetic disease and the best way to prevent the loss of sight from glaucoma is through early detection and treatment," said senior author Dr. Stuart MacGregor, head of the statistical genetics group at QIMR Berghofer Medical Research Institute. "Our study found that by analyzing DNA collected from saliva or blood, we could determine how likely a person was to develop the disease and who should be offered early treatment and or monitoring. Importantly, unlike existing eye health checks based on eye pressure or optic nerve damage, the genetic test can be done before damage begins so regular screening can be put in place. Having a high risk score does not mean you will definitely get glaucoma, but knowing you could be at future risk allows people to take the necessary precautions."

"We want to know who will get glaucoma, and for those who are susceptible, we want to be able to pinpoint at what age they are going to get it," said Dr. MacGregor. "That would allow us to develop a personalized approach for earlier treatment of high-risk individuals, and mean people at lower risk could have less intensive monitoring and treatment. This would have benefits for patients, doctors and the health care system with reduced interventions and reduced costs."

The paper was published in the January 20, 2020, online edition of the journal Nature Genetics.

Related Links:
QIMR Berghofer Medical Research Institute
Flinders University



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.